The enduring scientific question of whether the adult human brain can generate new neurons, a process known as neurogenesis, has long captivated researchers. Now, a groundbreaking study spearheaded by scientists at the USC Stem Cell and the USC Neurorestoration Center offers compelling evidence that adults can indeed replenish at least some lost brain cells. More significantly, the research reveals a dramatic alteration in this regenerative capacity in individuals suffering from long-term epilepsy, pointing towards a potential new avenue for therapeutic intervention. Published in the prestigious journal Nature Neuroscience, these findings hold profound implications for understanding and treating millions affected by this chronic neurological disorder.
Unveiling the Regenerative Capacity of the Adult Brain
For decades, the prevailing dogma suggested that the adult brain, once developed, possessed a finite number of neurons, with any loss being irreversible. However, accumulating evidence from various research groups has begun to chip away at this notion, indicating that pockets of neurogenesis persist throughout adulthood, particularly in specific regions like the hippocampus, a critical area for learning and memory. The USC study adds a crucial piece to this complex puzzle by directly examining living brain tissue obtained from human patients.
"Our study is the first to detail the presence of newborn neurons and an immature version of a related cell type, known as astroglia, in patients with epilepsy," stated Michael Bonaguidi, an assistant professor of stem cell biology and regenerative medicine, gerontology, and biomedical engineering at USC. This direct observation in living human brain tissue is a significant leap forward, moving beyond animal models and post-mortem analyses. The presence of these newly formed cells in the adult brain reinforces the idea that the human nervous system retains a remarkable capacity for self-repair.
The Impact of Long-Term Epilepsy on Neurogenesis
The most striking revelation from the USC research lies in the stark contrast observed between the brains of individuals with and without epilepsy. While newborn neurons were detected in both groups, their abundance and maturity were significantly affected by the presence of long-term epilepsy.
"In the samples from people both with and without epilepsy, the scientists observed newborn neurons, adding compelling new evidence to the ongoing scientific debate about whether adults retain the ability to generate these cells," the study details. However, the researchers discovered a critical correlation: "the longer the patients had experienced seizures, the scarcer these newborn neurons became." This suggests that the chronic inflammatory and excitotoxic environment associated with prolonged seizures may actively suppress or hinder the natural regenerative processes of the brain.
This finding is particularly relevant given the estimated prevalence of epilepsy. Globally, over 50 million people live with epilepsy, making it one of the most common neurological disorders. In many cases, the condition can be managed with medication, but a significant portion of patients, often referred to as having "refractory" or "drug-resistant" epilepsy, do not respond adequately to pharmacological treatments. This necessitates a deeper understanding of the underlying mechanisms driving the disease and the development of novel therapeutic strategies.
The Unexpected Role of Immature Astroglia
Beyond the reduction in newborn neurons, the study uncovered another surprising discovery: the presence of a persistent population of immature astroglia in the surgical specimens from epilepsy patients, a cell type not observed in disease-free samples. Astroglia, a type of glial cell, are traditionally understood as supporting cells for neurons, providing essential nutrients, maintaining the blood-brain barrier, and facilitating synaptic function. However, the USC team’s findings suggest a more complex and potentially detrimental role for immature astroglia in the context of chronic epilepsy.
"Our findings furnish surprising new insights into how immature astroglia might contribute to epilepsy — opening an unexplored avenue toward the development of new anti-seizure medications for millions of people," Bonaguidi elaborated. The research posits that these immature astroglia might not be passively supporting neurons but could actively be involved in the generation and propagation of seizures.
A Chronology of Discovery: From Surgical Specimens to Laboratory Insights
The study’s genesis lies in the invaluable contributions of patients undergoing surgical intervention for intractable epilepsy. For many individuals with drug-resistant epilepsy, particularly mesial temporal lobe epilepsy (MTLE), surgery to remove the affected brain region, often the hippocampus, is the last resort.
"Many patients bravely and generously donate their surgical specimens for research to advance our understanding of epilepsy and to develop new and better therapies," stated Jonathan Russin, an assistant professor of neurological surgery and associate director of the USC Neurorestoration Center. "These patients know better than anyone the trade-offs involved in the current treatment options, which often either don’t provide adequate seizure control, or carry very serious cognitive side effects."
The surgical specimens provided a unique opportunity to study living brain tissue. This allowed researchers, including first author Aswathy Ammothumkandy, a postdoctoral fellow in the Bonaguidi Lab, to not only analyze the microscopic anatomy of the tissue but also to cultivate stem cells derived from it in the laboratory. This dual approach provided both direct observational data and the ability to experimentally test cellular functions.
The laboratory experiments corroborated the direct observations. When stem cells from epilepsy patients were cultured, those from individuals with longer disease durations exhibited a diminished ability to form new neurons and an increased propensity to produce immature astroglia. This experimental validation strongly supports the hypothesis that the chronic epileptic state actively reshapes the brain’s cellular landscape, favoring the development of potentially problematic immature astroglia over regenerative neurogenesis.
Correlating Electrical Activity and Cellular Behavior
Further investigations delved into the electrical activity within the surgical samples, seeking to link the observed cellular abnormalities to the pathological manifestations of epilepsy. The researchers found "suspicious correlations between where electrical activity was localized within the surgical samples, and the location and behavior of the astroglia." This suggests that the immature astroglia may be strategically positioned and functionally active in areas prone to seizure generation.
Aswathy Ammothumkandy explained, "Normally, astroglia are considered to be supporting cells, because their job is to create an environment where neurons can thrive. But in patients who have lived for many years with epilepsy, it might be immature astroglia that are contributing to both initiating and modulating chronic seizures." This reimagining of astroglial function in the context of chronic epilepsy opens a new frontier in understanding seizure dynamics.
Implications for Future Therapies: Targeting Immature Astroglia
The identification of immature astroglia as potential contributors to seizure activity has significant therapeutic implications. Current anti-seizure medications primarily target neuronal function, aiming to dampen neuronal excitability. However, these medications can have limitations, including side effects and lack of efficacy in a substantial patient population.
"Currently available seizure medications tend to target neurons, so medications that act on immature astroglia could greatly expand the options for our patients," said Charles Liu, a professor of neurological surgery, neurology, and biomedical engineering, director of the USC Neurorestoration Center, and director of the USC Epilepsy Care Consortium. "A new class of drugs could combine with current medical and surgical strategies to control seizures without aggressive surgical removal of parts of the brain that can be critically important for learning, memory and emotional regulation."
The prospect of developing a new class of anti-seizure medications that specifically target immature astroglia offers a beacon of hope for individuals with drug-resistant epilepsy. Such a therapeutic approach could potentially offer a more targeted and effective way to manage seizures, thereby improving quality of life and reducing the need for invasive surgical procedures, which can carry significant cognitive and emotional consequences.
A Collaborative Endeavor: Bridging Disciplines for Innovation
This pioneering research was made possible through a multidisciplinary collaboration, fueled by initial pilot funding from an Eli and Edythe Broad Innovation Award, which champions faculty pursuing stem cell-related research collaborations. The project seamlessly integrated expertise from clinicians, scientists, and engineers across various institutions within the Keck School of Medicine of USC, including the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, the USC Neurorestoration Center, and the Zilkha Neurogenetic Institute. Furthermore, collaborations extended to the USC Epilepsy Care Consortium, the USC Viterbi School of Engineering, and the USC Davis School of Gerontology, as well as other universities and medical centers, highlighting the power of interdisciplinary science in tackling complex medical challenges.
The journey from initial observations to potential therapeutic breakthroughs is often a long and arduous one. However, the findings from the USC Stem Cell and Neurorestoration Center represent a significant stride forward in our understanding of the adult brain’s regenerative potential and its susceptibility to neurological disorders like epilepsy. By uncovering the intricate interplay between neurogenesis, the altered role of astroglia, and the chronic epileptic state, this research not only advances fundamental neuroscience but also illuminates a promising new pathway towards developing more effective treatments for millions worldwide. The dedication of epilepsy patients who contribute to research, coupled with the innovative spirit of scientists and clinicians, underscores the ongoing quest for a future where epilepsy is no longer a debilitating burden.